The study, published in the International Forum of Allergy & Rhinology, examined an automated deep learning-based sinus severity score known as SSS. The score is designed to quantify the amount of material blocking or filling the sinus cavities on computed tomography images. Researchers compared the automated measurement with the Lund-Mackay score, the established clinical and research method in which radiologists visually grade each sinus according to the degree of opacification. In both treatment trials, the automated system was more responsive to changes observed after therapy.

Chronic rhinosinusitis with nasal polyps is a long-lasting inflammatory disease affecting the nose and the air-filled spaces surrounding it. In people with the condition, inflamed tissue and soft, noncancerous growths called polyps can obstruct the nasal passages and interfere with drainage from the sinuses. Symptoms may include persistent nasal congestion, loss of smell, facial pressure and recurring infections. Because inflammation can involve several sinus compartments at once, CT imaging is frequently used to characterize the extent of disease and to assess whether treatment has altered the underlying sinus abnormalities.

The Lund-Mackay system has helped standardize CT interpretation for decades, but it remains dependent on human judgment. Radiologists assign scores to individual sinuses based largely on how much of each cavity appears opaque on the scan. Although the method is practical and widely accepted, visual categories can compress complex imaging information into relatively broad grades. Small changes may not be reflected when a sinus remains within the same scoring category, and different readers may interpret borderline findings differently. These limitations are especially important in clinical trials, where researchers need reliable measurements capable of detecting treatment effects.

The deep-learning SSS approaches the problem differently. Rather than asking a reader to place a sinus into a discrete visual category, the system analyzes the CT data computationally and estimates the proportion of each sinus that is opacified. Deep-learning models are trained on large collections of medical images to recognize patterns associated with anatomy and disease. Once trained, such a model can process new scans using the same algorithmic criteria each time. This quantitative approach may preserve more of the continuous information contained in a CT image, allowing researchers to identify modest reductions or increases in sinus disease that might be overlooked by categorical scoring.

“CT imaging gives us important information about what is happening inside the sinuses, but traditional scoring methods are subjective and may not capture smaller changes over time,” said Stephen M. Humphries, PhD, a researcher in the Department of Radiology at National Jewish Health and senior author of the study. “By using deep learning to quantify disease objectively, we have the potential to measure treatment response with greater precision.” The researchers’ comparison focused on responsiveness to change, a key property for a clinical-trial endpoint. A measurement that changes consistently when disease improves can help distinguish a genuine therapeutic effect from reader variability or random fluctuations.

The analysis drew on CT data from two randomized clinical trials evaluating the same treatment in patients with chronic rhinosinusitis with nasal polyps. When scans obtained before and after treatment were assessed, the automated score detected treatment-related differences more effectively than the Lund-Mackay score. Greater sensitivity does not necessarily mean that the algorithm replaces clinical assessment or proves that a patient feels better; rather, it indicates that the system may be better able to quantify radiographic change. CT findings must still be interpreted alongside symptoms, nasal examination, smell testing, polyp measurements and other outcomes that reflect the patient’s experience.

The potential impact extends beyond a single disease or medication. Clinical trials often require endpoints that are reproducible, sensitive and capable of showing whether a therapy affects the biological process it is intended to treat. If an imaging measure misses small but meaningful changes, investigators may need larger studies or longer follow-up periods to demonstrate efficacy. A more precise automated score could reduce measurement noise, improve statistical power and help researchers compare treatment responses across study populations. It may also provide a consistent framework for examining therapies with different mechanisms, including anti-inflammatory medicines, biologic drugs and surgical interventions.

The investigators emphasized that the findings should be interpreted within the limits of the study design. The model was tested using data from two clinical trials involving one treatment, so its performance with other therapies, scanners, patient populations and disease patterns remains to be established. CT images can vary according to acquisition settings and equipment, and an algorithm trained on one dataset may not perform identically in another clinical environment. Additional validation will be needed to determine whether the score remains accurate across hospitals and whether changes detected by the system correlate with outcomes that matter most to patients.

The work builds on earlier research using automated CT analysis in chronic sinus disease, including studies of patients with cystic fibrosis in which computational methods detected longitudinal changes in sinus opacification. Together, these findings point toward a broader role for artificial intelligence in respiratory imaging: not simply identifying whether disease is present, but measuring how it evolves over time. For chronic rhinosinusitis with nasal polyps, a condition that can persist or recur despite treatment, that distinction could be valuable. More objective imaging may help researchers understand treatment biology, identify subtle responses and design more informative trials, while clinicians continue to use imaging as one component of a comprehensive evaluation.

Subject of Research: Deep-learning analysis of sinus CT scans and treatment response in chronic rhinosinusitis with nasal polyps.

Article Title: Deep Learning Improves Sensitivity to Change in Sinus Computed Tomography: Evidence From Two Randomized Controlled Trials

Web References: International Forum of Allergy & Rhinology article; Stephen M. Humphries, PhD; National Jewish Health media resources

References: International Forum of Allergy & Rhinology. DOI: 10.1002/alr.70218. Article publication date: 16 July 2026.

Keywords: deep learning, artificial intelligence, sinus CT, computed tomography, chronic rhinosinusitis, nasal polyps, sinus opacification, Lund-Mackay score, treatment response, medical imaging, clinical trials, National Jewish Health

The central challenge addressed by MRICombo is the extreme diversity of MRI examinations. Scans can differ in magnetic-field strength, imaging sequences, spatial resolution, contrast settings, acquisition protocols and patient positioning. Hospitals may also use different scanners and software, producing images that look substantially different even when they depict the same anatomical structure. These variations can make it difficult for an algorithm trained on one dataset to perform consistently on another. A model that appears highly accurate in a single research environment may lose reliability when confronted with images from a different institution.

MRICombo is presented as a universal framework for heterogeneous MRI, meaning that its architecture is intended to work across a broad range of imaging conditions rather than being narrowly tied to one scanner or one standardized protocol. In technical terms, such a system must learn disease-related visual patterns while resisting irrelevant changes caused by image acquisition. This is a major distinction: the algorithm needs to recognize the biological signal of a lesion, not simply memorize the appearance of the machines or datasets used during training.

One of the framework’s key functions is volumetric segmentation. Instead of identifying a suspicious region on a single two-dimensional slice, volumetric segmentation attempts to outline the full three-dimensional extent of a structure or lesion across the entire MRI examination. This can provide information about tumor volume, shape, spatial distribution and relationship to surrounding tissue. Three-dimensional analysis is particularly important when abnormalities extend irregularly through an organ, because a slice-by-slice assessment may underestimate their size or fail to capture their complete geometry.

The framework also combines image segmentation with grading and staging, two clinical tasks that answer different questions. Grading generally concerns how aggressive or abnormal a tumor appears under a disease-specific classification system, while staging evaluates how far the disease has progressed. Integrating these tasks with anatomical delineation could allow the system to connect what a lesion looks like with where it is located and how extensively it has spread. In principle, this multitask strategy may help an algorithm learn shared features across related objectives, although the quality of any clinical conclusion still depends on the data, labels and validation methods used to develop it.

Malignancy detection adds another layer to the proposed system. Rather than focusing solely on drawing boundaries around an abnormality, MRICombo is designed to distinguish malignant disease from non-malignant findings. That distinction is often difficult even for experienced radiologists because benign lesions, inflammation, treatment-related changes and early cancers can overlap in appearance. A deep-learning model can analyze thousands of quantitative image patterns simultaneously, including intensity distributions, texture, shape and spatial context. However, such complexity also makes careful evaluation essential, since a prediction is only useful when its accuracy and limitations are understood.

The promise of a combined framework is not simply speed. If one validated model could support several stages of MRI interpretation, it might reduce repetitive manual work and generate standardized measurements for multidisciplinary teams. A consistent three-dimensional lesion volume, for example, could help with treatment planning or monitoring changes over time. Automated grading and staging estimates might also serve as an additional reference during clinical review. Yet these possibilities should be viewed as decision-support applications rather than a replacement for physicians, pathology, clinical history or expert radiological judgment.

The study’s emphasis on heterogeneity is especially timely as medical imaging becomes increasingly distributed across hospitals, regions and healthcare systems. Artificial intelligence that performs well only on carefully curated images has limited real-world value. Universal or general-purpose imaging models must be tested against differences in patient populations, scanner manufacturers, imaging protocols and disease prevalence. They must also be assessed for hidden biases, calibration errors and failures in uncommon cases. For MRICombo, the significance of the work will therefore depend not only on its reported performance, but also on how broadly and transparently the framework is validated.

MRICombo represents a broader shift in medical AI: moving from isolated algorithms built for one narrow task toward integrated systems capable of handling an entire chain of image-based assessment. The concept is compelling because cancer diagnosis and management rarely depend on a single measurement. Clinicians need to know what a lesion is, where it is, how large it is, how aggressive it may be and whether it is malignant. By placing these questions within one deep-learning framework, the study offers a vision of more connected MRI analysis. The next test will be whether that vision can translate across institutions and ultimately improve decisions for patients in everyday clinical practice.

Subject of Research: A deep-learning framework for volumetric MRI segmentation, tumor grading, disease staging and malignancy detection across heterogeneous MRI data.

Article Title: MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.

Article References: Zhang, Z., Han, L., Jia, D. et al. “MRICombo: a deep-learning-based framework for universal volumetric segmentation grading-staging and malignancy detection across heterogeneous MRI.” Nature Communications (2026). https://doi.org/10.1038/s41467-026-76461-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76461-z

Keywords: MRI, deep learning, medical imaging, volumetric segmentation, tumor grading, cancer staging, malignancy detection, heterogeneous imaging data, artificial intelligence.

For years, radiologists have been the frontline defense against lung cancer, meticulously analyzing CT scans to pinpoint tumors for treatment deliberation. However, this process is labor-intensive and fraught with variability—different physicians may interpret the same scans differently, leading to discrepancies in diagnosis and treatment planning. The emergence of artificial intelligence, particularly deep learning techniques, presents a transformative opportunity to reduce human error and streamline workflows. The authors of the study highlighted that existing AI applications to date have suffered from limitations such as small sample sizes and an over-reliance on manual adjustments, thus emphasizing the need for models that can operate autonomously across diverse clinical environments.

In their retrospective analysis, the researchers developed a near-expert-level model using a dataset composed of 1,504 pre-radiation treatment CT simulation scans. This corpus included 1,828 delineated lung tumors, establishing a robust foundation for training their 3D U-Net architecture model. The model’s unique three-dimensional approach allows it to utilize interslice information, thus enhancing its capability to detect smaller lesions that might be misidentified by traditional two-dimensional models. This multidimensional processing strength is a significant advantage, potentially leading to improved diagnostic accuracy.

The experimental framework involved dividing the CT scans into a training set, where the model learned to recognize the nuances of tumor characteristics, and a separate test set comprising 150 CT scans. Each model-predicted tumor volume was meticulously compared against physician-delineated volumes, employing an array of performance metrics to gauge efficacy. The results were striking; the model achieved a sensitivity of 92% in detecting lung tumors, paired with an 82% specificity rate. This indicates that the model is not only proficient at identifying true positives but also adept at minimizing false positives, a critical aspect in clinical decision-making.

Segmentation accuracy was further assessed in a subset of these scans, revealing a median Dice similarity coefficient (DSC) of 0.77 when comparing model segmentations against physician evaluations. In contrast, the corresponding physician-physician DSC was recorded at 0.80. This marginal difference highlights the potential of AI systems to reach near-human-level performance while offering significant time savings over manual segmentation efforts performed by medical practitioners. The findings underscore an essential narrative: AI does not aim to replace physicians but rather to augment their capabilities and efficiency.

Although the results are promising, the researchers cautioned against potential pitfalls, notably the model’s tendency to underestimate tumor volume, particularly in larger tumors. This highlights an essential vigilance required in implementing AI solutions within clinical workflows—physicians must account for and supervise any deviations in automated assessments to ensure patient safety and treatment efficacy. The authors advocate for a collaborative ecosystem wherein AI serves as a supplementary tool that enhances, rather than supplants, clinical acumen.

As the study concludes, Dr. Mehr Kashyap, the lead author and a resident physician at Stanford University School of Medicine, envisions a paradigm shift in lung cancer management driven by this technology. He emphasizes the importance of conducting longitudinal studies to ascertain the model’s potential to evaluate treatment responses over time and its capability to predict clinical outcomes based on tumor burden assessments. Such undertakings could yield data-rich insights that can significantly influence how oncologists approach lung cancer care.

Furthermore, the researchers pointed out the urgent need for future investigations to tackle broader applications—specifically, using this model for comprehensive lung tumor burden estimation. As treatment modalities evolve, understanding how distinct tumor burdens associate with clinical outcomes could provide critical insights that empower oncologists to develop tailored treatment plans. This depth of understanding may not only enhance treatment efficacy but also facilitate ongoing monitoring, allowing for adaptive treatment strategies aligned with the patient’s journey through cancer care.

In the vibrant discourse surrounding AI and healthcare, this study serves as an essential reminder of the balance between technological innovation and human oversight. The intersection of AI capabilities with the sensitivities inherent in medical treatment points toward a future where machine learning can significantly augment diagnostic practices while still requiring the critical interpretations of skilled clinicians. The authors encapsulate this notion, envisioning an integrated system where both AI and human expertise collaborate to provide the best possible patient outcomes.

This research not only marks a significant leap in the utilization of AI in radiology but also sets a foundation for reimagining protocols in cancer diagnostics and treatment decisions. As deep learning continues to evolve, the integration of such advanced models may unfold new frontiers in personalized medicine, where patients receive tailored interventions based on precise tumor identifications and burden assessments. The anticipation buzzes not merely due to the advancement in technology but because of its potential to save lives and transform clinical practice fundamentally.

In summary, the development of this deep learning model signifies an exciting chapter in the ongoing evolution of medical imaging and oncology. With a strong foundation set forth by pioneering researchers and a clear pathway outlined for future research, the days ahead hold promise for both clinicians and patients alike as the intersection of technology and medical science continues to pave the way for transformative healthcare solutions.

Subject of Research: Lung Tumor Detection and Segmentation
Article Title: Automated Deep Learning-Based Detection and Segmentation of Lung Tumors at CT
News Publication Date: 21-Jan-2025
Web References: Radiology Journal
References: Mehr Kashyap, M.D., et al. "Automated Deep Learning-Based Detection and Segmentation of Lung Tumors at CT." Radiology.
Image Credits: Radiological Society of North America

Keywords: Lung tumors, Lung cancer, Computerized axial tomography, Deep learning